Doctor Dismisses GLP-1 Hair Loss: Why It Keeps Happening

Updated 2026-04-19 9 min read By Provant Labs Research Team

The FDA label for Wegovy lists alopecia as an adverse event. The FDA label for Zepbound lists it. Multiple Phase 3 clinical trials document it. A real-world cohort study of 547,993 patients shows GLP-1 users had 1.76 times higher adjusted odds of telogen effluvium than matched controls. And yet: thousands of women walk out of appointments every week having been told the hair loss is "just stress" or "probably hormones."

Here's why that disconnect exists, and what you can do about it.

"It's Just Stress": The Most Common Wrong Answer

The frustration is real. You go to your PCP or OB-GYN with handfuls of hair, and you get a response that functions as dismissal: "Are you under stress? Have you had any major life changes?"

And here's the thing: stress does cause hair loss. Telogen effluvium is triggered by any significant physiological or psychological stressor. Surgery, illness, pregnancy, rapid weight loss, severe emotional stress. So "stress" as an explanation isn't technically wrong. It's just incomplete in a way that fails you.

The specific stressor in your case is rapid weight loss driven by a GLP-1 medication. Acknowledging that is clinically useful. It predicts when the shedding will likely peak, when it will slow down, and what nutritional gaps to address. "It's stress" tells you nothing actionable.

But many PCPs don't make this connection, and the reasons are structural.

Why PCPs Miss It: The Structural Problem

Primary care physicians prescribe most GLP-1 medications in the United States. They're not metabolic specialists, endocrinologists, or dermatologists. They're managing 20+ conditions per patient, operating on 15-minute appointments, and working through prescription software that often auto-populates the most common drug effects in the simplest language.

When GLP-1s first reached mass prescribing levels in 2022-2023, the conversation was almost entirely about efficacy: weight loss, A1c reduction, cardiovascular outcomes. The adverse event profile, including alopecia, didn't receive significant attention in CME content or prescriber materials.

And honestly? Alopecia ranks relatively low in the FDA adverse event severity hierarchy. It's not life-threatening. It doesn't affect organ function. In a clinical framework designed around mortality and morbidity, hair loss occupies a lower priority tier. Prescribers who internalized the efficacy data may not have internalized the quality-of-life data.

The result: a patient experiencing significant, distressing hair loss brings it to a prescriber who genuinely doesn't connect it to the medication.

What the Science Actually Shows

This is documented at multiple levels of evidence, not just in case reports or forums.

FDA labels. The Wegovy label reports alopecia in 3% of semaglutide patients vs 1% placebo. The Zepbound label reports 5% vs 1%, with women specifically at 7.1% vs 0.5% for men. These are Phase 3 randomized controlled trial numbers. They're in the official prescribing information.

SURMOUNT-1 (Jastreboff et al., NEJM 2022, n=2,539, 72 weeks): 5.1% of patients on 5mg tirzepatide experienced alopecia vs 0.9% on placebo. At 10mg: 5.3%. At 15mg: 4.9%.

OASIS 1 (Knop et al., Lancet 2023, n=667): 6.9% of patients on oral semaglutide 50mg experienced alopecia, vs the placebo group.

TriNetX real-world cohort study (2025): Using data from 67 healthcare organizations covering more than 100 million patients, matched cohorts of 547,993 patients showed GLP-1 users had an adjusted odds ratio of 1.76 (95% CI: 1.34-2.32) for telogen effluvium, 1.64 for androgenic alopecia, and 1.40 for nonscarring hair loss overall, at 12 months.

Etminan et al. (2025, medRxiv, n=1,926): Women on semaglutide had a hazard ratio of 2.08 (95% CI: 1.17-3.72) for hair loss compared to bupropion-naltrexone users. The risk was not significant in men (HR: 0.86).

This is not ambiguous science. It's not five Reddit posts. It's FDA labels, Phase 3 RCTs, and a real-world cohort of half a million people.

The Ferritin Gap: Where Good Doctors Still Miss It

There's a second dismissal pattern that even well-intentioned, knowledgeable prescribers fall into. And this one requires understanding the difference between "normal" and "adequate."

When doctors order blood work for hair loss, they'll typically check TSH (thyroid), ferritin (iron stores), and maybe vitamin D. If those come back in the "normal" range on the lab report, the conversation often ends there.

But here's the gap: laboratory "normal" ranges for ferritin are designed around general population health, not hair health specifically. The standard low end of "normal" ferritin is typically 12-20 ng/mL on most lab printouts. Your GP might circle your ferritin of 28 ng/mL and call it fine.

Hair specialists don't agree. The clinical guidance in dermatology consistently points to ferritin above 70 ng/mL as the threshold for adequate follicle support. Some practitioners set it at 80-100 ng/mL for women experiencing active shedding.

The gap between "normal at 28" and "adequate at 70" is where a lot of GLP-1 hair loss lives. And it's a gap your GP may not know exists, because they learned the lab reference range, not the hair-specific threshold.

GLP-1 medications compound this. Appetite suppression dramatically reduces caloric intake. Reduced caloric intake means reduced iron intake. Iron depletion takes months to show up in ferritin (ferritin is a storage protein, not a real-time marker). By the time your ferritin drops to 28 ng/mL, you've been iron-depleted for months.

Studies to Bring to Your Appointment

If you're facing dismissal, specific data is more effective than describing symptoms. Here's what to cite:

For the GLP-1 connection:

"The FDA prescribing information for Wegovy lists alopecia in 3% of patients vs 1% placebo. For Zepbound, it's 5% vs 1%, with women at 7.1%."
"A 2025 real-world cohort study using data from 67 healthcare organizations (n=547,993 matched patients) found 1.76 times higher odds of telogen effluvium in GLP-1 users."
"A 2025 analysis by Etminan et al. in medRxiv found a hazard ratio of 2.08 for women on semaglutide."

For the ferritin threshold:

"Multiple dermatology guidelines recommend ferritin above 70 ng/mL for adequate follicle support. My lab shows X, which is within the standard reference range but below the hair-specific threshold."
Ask explicitly: "Can we retest ferritin with the target of 70+ ng/mL rather than the lab's standard reference range?"

For the mechanism:

"Telogen effluvium from rapid weight loss is documented in the dermatology literature, including a 2024 retrospective cohort study (Annals of Dermatology, n=140) that showed onset at 1.12 months post-weight loss and recovery at 4.83 months without treatment."

You're not trying to win an argument. You're trying to get the right labs ordered and have an informed conversation about timeline.

What a Good Prescriber Response Looks Like

Not every dismissal is malicious or even negligent. Some prescribers simply haven't updated their knowledge on this specific topic. A good response to raising these concerns looks like:

"Let me order ferritin, zinc, and a complete metabolic panel to check for nutritional gaps."
"Your shedding pattern is consistent with telogen effluvium secondary to rapid weight loss. That's the likely mechanism."
"The shedding should slow as your weight stabilizes, typically around months 6-9 of treatment. Let's check back at 3 months."
Discussion of whether a dose modification makes sense for your specific situation.

A bad response looks like: "Hair loss is just normal for your age" or "That's not a known side effect of this medication."

If you're getting the second response after bringing the data above, getting a second opinion from a dermatologist or endocrinologist is reasonable. They're more likely to have updated clinical knowledge on GLP-1 side effects.

What to Do Right Now (Before Your Next Appointment)

You don't need your doctor to take action before your next appointment.

Get labs ordered. Ask for ferritin, zinc, vitamin D, and TSH. You can request these at any appointment, not just one focused on hair loss. If your ferritin comes back below 70, that's actionable even without a prescriber acknowledging the GLP-1 connection.

Track protein intake. GLP-1 appetite suppression makes hitting 60-100g of protein daily difficult. Use a simple tracking app for a week to see where you actually land. Most GLP-1 users are significantly below this threshold.

Start topical scalp support. You don't need a prescription and you don't need your doctor's acknowledgment to address the follicle environment directly. Topical rosemary extract (Panahi et al. 2015, SKINmed, n=100, comparable to minoxidil 2% at 6 months) and saw palmetto (Sudeep et al. 2023, n=80, 22% shedding reduction) are available OTC and have RCT support.

Document the shedding. Count hairs on a specific surface for 60 seconds, twice weekly. Note any changes in ponytail circumference. This objective data is more useful in a clinical conversation than "I feel like it's getting worse."

The Patients Who Get Dismissed Most Often

Two patterns show up consistently in the literature and in GLP-1 user communities:

Women over 45. The overlap of GLP-1 hair loss with perimenopause hair thinning creates confusion for prescribers. When a 47-year-old presents with diffuse shedding, "hormones" is an easy default. The answer that serves you is: "It's probably both, and they need to be addressed as compound factors."

Women with 'normal' labs. If your TSH, B12, and iron come back in normal range, the conversation often ends there. But normal iron (serum iron, hematocrit) is not the same as adequate ferritin. Normal B12 is not the same as optimal. The lab reference ranges tell you where you are relative to a broad population, not where you need to be for follicle health during caloric restriction.

FAQ

My doctor says Ozempic doesn't cause hair loss. What do I do?

The FDA prescribing information for Wegovy (the obesity indication) explicitly lists alopecia as an adverse event at 3% vs 1% placebo. For Zepbound, it's 5% vs 1%. A real-world cohort of 547,993 matched patients showed 1.76 times higher odds of telogen effluvium in GLP-1 users. Bring these specific data points to your next appointment and ask for ferritin, zinc, and TSH to be checked.

Is GLP-1 hair loss listed on the FDA label?

Yes. The Wegovy label lists alopecia. The Zepbound label lists alopecia. Neither Ozempic nor Mounjaro (the diabetes-indication versions at lower doses) list it as prominently, which may explain some prescriber confusion. The hair loss pattern is most documented in the obesity-indication high-dose GLP-1s.

Why do some doctors say it's just stress?

Stress does cause telogen effluvium, and rapid weight loss is a physiological stress. So technically, "stress" is correct. But it's incomplete in a way that fails the patient. The specific stressor is the medication-driven weight loss, and identifying it allows for a timeline prediction and targeted nutritional support. "Just stress" without that context leads to no action.

What ferritin level should I target?

Hair specialists consistently recommend ferritin above 70 ng/mL for adequate follicle support, compared to the standard lab reference range low end of 12-20 ng/mL. Ask your provider to check ferritin specifically, and ask what the result is in numerical terms, not just "normal" or "abnormal."

Should I see a dermatologist about GLP-1 hair loss?

Dermatologists and trichologists (hair specialists) are significantly more likely than PCPs to have current knowledge on GLP-1-related telogen effluvium. If your PCP is dismissing the connection, a dermatologist consultation is worth pursuing. They can also rule out androgenic alopecia, which has different treatment implications, and order the specific labs (dermatoscopy, phototrichogram, or trichoscopy) that give the clearest picture of what's happening at the follicle level.

How long before my doctor takes this seriously?

Prescriber knowledge on GLP-1 side effects is improving rapidly as the medications reach mass scale. A 2025 cohort study of 547,993 patients is the kind of data that changes clinical practice guidelines. But the lag between published research and updated prescriber behavior is typically 2-5 years. You may need to be the one who brings this to your provider's attention.

Ready to support your hair during your GLP-1 journey?

See the PD-5 Complex